FOSAPREPITANT for injection (FOS a PRE pi tant)
for intravenous use
What is Fosaprepitant for Injection?
Fosaprepitant for Injection is a prescription medicine used with other medicines that treat nausea and vomiting in adults to prevent nausea and vomiting caused by certain anti-cancer (chemotherapy) medicines.
Do not receive Fosaprepitant for Injection if you:
Before receiving Fosaprepitant for Injection, tell your healthcare provider about all your medical conditions including, if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Fosaprepitant for Injection may affect the way other medicines work, and other medicines may affect the way Fosaprepitant for Injection works , causing serious side effects.
Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.
How will I receive Fosaprepitant for Injection?
Fosaprepitant for Injection will be given on Day 1 of chemotherapy treatment. It will be given to you by intravenous (IV) infusion in your vein about 50 to 60 minutes before you start your chemotherapy treatment.
If you take the blood thinner medicine warfarin sodium (COUMADIN, JANTOVEN), your healthcare provider may do blood tests after you receive Fosaprepitant for Injection to check your blood clotting.
What are the possible side effects of Fosaprepitant for Injection?
Fosaprepitant for Injection may cause serious side effects, including:
Most severe ISR have happened with a certain type of chemotherapy medicine that can burn or blister your skin (vesicant) with side effects, including pain, swelling and redness. Death of skin tissue (necrosis) has happened in some people getting this type of chemotherapy medicine. Most ISR can happen with the first, second, or third dose and some can last up to 2 weeks or longer. Tell your healthcare provider right away if you get any infusion site side effects.
The most common side effects of Fosaprepitant for Injection include:
| || |
| || |
| || |
| || |
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of Fosaprepitant for Injection. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of Fosaprepitant for Injection.
If you would like more information about Fosaprepitant for Injection, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about Fosaprepitant for Injection that is written for health professionals. For more information about Fosaprepitant for Injection call Teva Pharmaceuticals USA, Inc. at 1-888-838-2872.
What are the ingredients in Fosaprepitant for Injection?
Active ingredient: fosaprepitant dimeglumine
Inactive ingredients: edetate disodium, meglumine, povidone k12, and water for injection. Hydrochloric acid and/or meglumine may have been added for pH adjustment.
Brands listed are trademarks of their respective owners.
Manufactured by: Actavis Italy, S.p.A., Via Pasteur 10, Nerviano, Italy 20014 or Sindan Pharma SRL , 11th Ion Mihalache Blvd., Bucharest 1, Romania 011171
Manufactured for: Teva Pharmaceuticals USA, Inc. North Wales, PA 19454
This Patient Information has been approved by the U.S. Food and Drug Administration. Iss. 9/2019
Fosaprepitant for Injection
Sterile Lyophilized Powder for Intravenous Use Only After Reconstitution and Dilution
DO NOT USE WITH SOLUTIONS CONTAINING DIVALENT CATIONS (e.g., Ca2+ , Mg2+) INCLUDING LACTATED RINGER’S SOLUTION AND HARTMANN’S SOLUTION.
Each vial contains:
(equivalent to 245.3 mg of fosaprepitant dimeglumine)
Discard Unused PortionTeva
|FOSAPREPITANT fosaprepitant injection, powder, lyophilized, for solution|
|Labeler — Actavis Pharma, Inc. (119723554)|
Revised: 09/2019 Actavis Pharma, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.